viewMedlab Clinical Ltd

Medlab Clinical researching links between gut microbiome and multiple chronic diseases

Medlab Clinical Ltd (ASX:MDC) CEO & managing director Dr. Sean Hall tells Proactive Investors, "probably one of the biggest things in medicine to date" is research into the human microbiome and its impact on human health.

Modern research on the field stems from The Human Microbiome Project conducted by the US National Institute of Health starting in 2008, intended to broaden medical understanding of the role of bacteria living in and on humans.

Medlab has taken particular interest in the gut microbiome, and its connection with various chronic diseases. Research into the link with depression is the most advanced, with human patients currently being recruited for Phase IIA clinical trials of NRGBiotic™. The biotech is also researching and developing probiotic applications for the treatment and management of diabetes and chronic kidney disease.

Quick facts: Medlab Clinical Ltd

Price: 0.245 AUD

Market: ASX
Market Cap: $68.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...


Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read